Jardiance vs Lantus: Combining the Two (Rationale + Risk)

What Jardiance and Lantus Actually Do (Mechanism Overview)

Empagliflozin and insulin glargine occupy non-overlapping positions in the glycemic control cascade. Understanding both mechanisms is the foundation for understanding why combination therapy makes clinical sense, and where the risks originate.

How Jardiance Lowers Blood Sugar

Empagliflozin belongs to the sodium-glucose cotransporter-2 (SGLT2) inhibitor class. It blocks SGLT2 proteins in the proximal tubule of the kidney, preventing reabsorption of roughly 60 to 90 grams of glucose per day, which is then excreted in the urine. [1] This glucosuria is entirely insulin-independent, meaning the drug works even when beta-cell function is severely diminished. The result is a modest but consistent HbA1c reduction of approximately 0.5 to 1.0% from baseline in most randomized trials. [2]

Beyond glycemia, empagliflozin reduces systolic blood pressure by 3 to 5 mmHg through osmotic diuresis and natriuresis, [3] and produces a mean weight loss of 2 to 3 kg over 24 to 52 weeks. [4]

How Lantus Lowers Blood Sugar

Insulin glargine is a long-acting basal insulin analogue designed to provide a flat, peakless 24-hour insulin profile. After subcutaneous injection, it forms microprecipitates that release insulin slowly. [5] Its primary action is suppression of hepatic glucose output overnight and between meals, keeping fasting plasma glucose in range. The ORIGIN trial (N=12,537) demonstrated that titrating glargine to a fasting glucose target of 5.3 mmol/L (95 mg/dL) was safe and did not increase cardiovascular events over a median 6.2 years of follow-up. [6]

Glargine does not address postprandial glucose spikes directly. That gap is one reason clinicians add agents such as empagliflozin.

Why the Two Mechanisms Complement Each Other

Insulin controls fasting glucose via hepatic suppression and peripheral uptake. Empagliflozin controls both fasting and postprandial glucose via renal excretion, entirely outside the insulin pathway. The two drugs therefore attack different glucose pools simultaneously. [7] Adding empagliflozin to established basal insulin therapy also creates a modest caloric deficit through glycosuria (roughly 240 to 360 kcal/day at full glucose excretion) [8], which partially offsets the mild weight gain that can accompany insulin titration.

Clinical Evidence for the Combination

Three categories of evidence support combining empagliflozin with basal insulin: dedicated add-on trials, the EMPA-REG OUTCOME cardiovascular outcomes trial, and real-world registry data.

Add-On Trials: Glycemic Outcomes

A randomized, double-blind trial published in Diabetes Care (N=495) evaluated empagliflozin 10 mg and 25 mg added to basal insulin (with or without metformin) over 78 weeks. Both doses produced statistically significant HbA1c reductions versus placebo: -0.57% (10 mg) and -0.59% (25 mg) at 78 weeks. [9] Fasting plasma glucose fell by 17 to 21 mg/dL, and body weight decreased by approximately 2 kg in both empagliflozin groups while rising slightly in the placebo group.

A parallel 52-week study (N=563) tested empagliflozin added to basal-bolus insulin regimens and found similar HbA1c reductions of 0.5 to 0.6%, with a bolus insulin dose reduction of roughly 11 to 12 units/day in the empagliflozin arms. [10]

EMPA-REG OUTCOME: Cardiovascular and Renal Signals

EMPA-REG OUTCOME enrolled 7,020 adults with T2D and established cardiovascular disease, randomized to empagliflozin 10 mg, 25 mg, or placebo added to standard of care. [11] Approximately 48% of participants were on basal insulin at baseline. The trial showed a 38% relative reduction in cardiovascular death (HR 0.62, 95% CI 0.49 to 0.77, P<0.001), a 35% reduction in hospitalization for heart failure (HR 0.65, 95% CI 0.50 to 0.85), and a 39% reduction in incident or worsening nephropathy. [11]

These benefits were consistent in the insulin-using subgroup, establishing that the cardiorenal protection of empagliflozin is not blunted by concomitant insulin therapy. [12]

ORIGIN: Establishing Glargine's Safety Floor

ORIGIN (N=12,537) remains the landmark trial for basal insulin safety. Participants with dysglycemia or early T2D were randomized to insulin glargine or standard care. After a median 6.2 years, glargine did not increase myocardial infarction, stroke, or death from cardiovascular causes. [6] The trial also recorded a median weight gain of 1.6 kg in the glargine arm versus 0.5 kg in standard care, a small but real signal that is clinically relevant when choosing combination partners.

Who Should Receive the Combination

The combination is not right for every patient. Selecting appropriate candidates requires examining CV risk status, kidney function, baseline HbA1c, and hypoglycemia history.

Patients With Established ASCVD, Heart Failure, or CKD

The 2024 ADA Standards of Medical Care in Diabetes explicitly recommends adding an SGLT2 inhibitor (with proven benefit) to background therapy, including basal insulin, for patients with T2D and established atherosclerotic cardiovascular disease, heart failure with reduced or mildly reduced ejection fraction, or CKD with albuminuria (urine albumin-to-creatinine ratio >30 mg/g). [13] This recommendation is independent of HbA1c level. The ADA guideline states: "For patients with T2D and established cardiovascular disease, an SGLT2 inhibitor with proven cardiovascular benefit is recommended to reduce the risk of major adverse cardiovascular events and/or hospitalization for heart failure." [13]

Patients Requiring Insulin Who Are Overweight or Obese

Glargine frequently causes modest weight gain of 1 to 3 kg over 12 to 24 months, [6] which can be clinically frustrating for patients already managing obesity. Empagliflozin's 2 to 3 kg weight reduction [4] partially counteracts this, making the combination pharmacologically rational for patients with a BMI above 30 kg/m² who need basal insulin.

Patients With Suboptimal Fasting Glucose Despite Uptitrated Basal Insulin

Some patients reach glargine doses of 50 to 80 units/day and still carry HbA1c values above 8.0%. Before escalating to basal-bolus therapy (which multiplies injection burden and hypoglycemia risk), adding empagliflozin 10 mg can produce a meaningful additional 0.5 to 0.6% HbA1c reduction without adding injections. [9]

When the Combination Is Not Appropriate

Empagliflozin should not be added to insulin in patients with eGFR <45 mL/min/1.73 m² for glycemic purposes (the FDA label restricts initiation below this threshold). [14] It is also contraindicated in T1D outside clinical trials due to DKA risk. Patients with a history of recurrent diabetic ketoacidosis, very low carbohydrate diets, or significant alcohol use carry elevated euglycemic DKA risk and require individualized assessment. [15]

Dosing the Combination: Starting Points and Titration

Combining two glucose-lowering agents that work by different mechanisms requires a structured approach to avoid hypoglycemia at initiation and to capture the full long-term benefit of both drugs.

Starting Empagliflozin in a Patient Already on Glargine

The standard starting dose of empagliflozin is 10 mg once daily in the morning, regardless of meals. [14] When adding it to an established glargine regimen, most randomized trials proactively reduced basal insulin by 10 to 20% at the time of empagliflozin initiation to reduce hypoglycemia risk. [9] The 2024 ADA guidelines support a similar approach: clinicians should consider a 10 to 20% basal insulin dose reduction when starting any SGLT2 inhibitor in insulin-treated patients. [13]

Fasting glucose should be rechecked at 2 to 4 weeks. If it remains above target (typically 80 to 130 mg/dL per ADA guidance), glargine can be up-titrated by 2 units every 3 days using a standard treat-to-target algorithm. [13]

Starting Glargine in a Patient Already on Empagliflozin

Initial glargine dosing follows standard body-weight protocols: 0.1 to 0.2 units/kg/day for insulin-naive patients, or a conversion from oral agent failure. [16] No fixed pre-emptive dose reduction of empagliflozin is required, but patients should receive education on recognizing hypoglycemia symptoms, which can be blunted by the osmotic diuresis and caloric loss effects of ongoing SGLT2 blockade. [15]

Titration Targets

The ADA recommends a fasting plasma glucose target of 80 to 130 mg/dL for most non-pregnant adults with T2D and an HbA1c target of <7.0% for most patients, with individualized targets for those with hypoglycemia unawareness, limited life expectancy, or extensive comorbidities. [13] Combination titration should be guided by both fasting glucose (glargine dose) and HbA1c trajectory (both agents).

Risks and How to Manage Them

The combination of an SGLT2 inhibitor and basal insulin carries a specific set of risks that differ from either drug used alone. These require patient education and a monitoring plan.

Hypoglycemia

Empagliflozin alone carries negligible hypoglycemia risk because its mechanism is insulin-independent. [2] Adding it to insulin changes this picture. The 78-week add-on trial recorded confirmed hypoglycemia (<70 mg/dL) in 27.1% of patients on empagliflozin 10 mg plus basal insulin versus 20.6% in the placebo plus basal insulin group. [9] The difference was driven by protocol-mandated maintenance of pre-study insulin doses in a subset; trials that proactively reduced insulin by 20% at initiation showed smaller incremental hypoglycemia rates. [10]

Patients should be counseled to keep fast-acting glucose (glucose tablets, juice) on hand, especially during the first 4 to 8 weeks of combination therapy. Nocturnal hypoglycemia deserves particular attention because glargine peaks subtly in the early morning hours in some patients despite its "peakless" labeling.

Euglycemic Diabetic Ketoacidosis

Euglycemic DKA is the most serious unique risk of SGLT2 inhibitors used with insulin. It can occur with glucose levels well below the classic 250 mg/dL threshold, making it easy to miss. [15] Predisposing factors include prolonged fasting, very low carbohydrate intake, surgical stress, heavy alcohol use, and aggressive insulin dose reduction. [15]

The FDA issued a drug safety communication in 2015 warning about this risk across all approved SGLT2 inhibitors, including empagliflozin. [17] Clinicians should advise patients to hold empagliflozin at least 3 days before any elective surgery or prolonged fasting procedure. [14]

Genitourinary Infections

Glucosuria creates a substrate-rich environment for fungal and bacterial growth. Clinical trials show genital mycotic infections in approximately 5 to 10% of women and 3 to 6% of men on empagliflozin. [4] Urinary tract infections occur at a modestly elevated rate. These are generally mild and treatable but warrant counseling at initiation.

Volume Depletion and Renal Function

The osmotic diuresis from empagliflozin reduces plasma volume by a mean of approximately 7%, which lowers blood pressure but can cause dizziness or acute kidney injury in volume-depleted states. [3] Patients on diuretics, ACE inhibitors, or ARBs require monitoring of serum creatinine, electrolytes, and blood pressure within 4 to 8 weeks of starting empagliflozin. [14]

Should You Switch From Jardiance to Lantus, or Add One to the Other?

This is one of the most common clinical decision points, and the answer depends on why the switch is being considered.

Scenarios Favoring a Switch (Discontinue Empagliflozin, Start Glargine)

A pure switch from empagliflozin to glargine is appropriate when a patient's beta-cell function has declined to the point that insulin secretion is insufficient to meet even basal needs, a state where the insulin-independent mechanism of SGLT2 inhibition can no longer compensate. Clinically, this presents as progressive fasting hyperglycemia despite maximally tolerated oral/injectable non-insulin therapy, with HbA1c rising above 9.0 to 10.0% and fasting glucose consistently above 200 to 250 mg/dL. [13]

Switching is also appropriate when eGFR falls below 45 mL/min/1.73 m², which removes empagliflozin's glycemic efficacy while leaving glargine fully effective. [14]

Scenarios Favoring Addition (Keep Empagliflozin, Add Glargine)

For patients with established ASCVD, HF, or CKD who progress to needing basal insulin, stopping empagliflozin to "simplify" the regimen sacrifices cardiorenal protection that has strong outcomes-trial support. Adding glargine while continuing empagliflozin, with appropriate insulin dose reduction and monitoring, is the preferred strategy according to current ADA and AACE guidance. [13, 18]

The AACE 2023 Comprehensive Diabetes Management Algorithm states that SGLT2 inhibitors with proven CV/renal benefit should be continued even when insulin is added, unless tolerability or safety concerns emerge. [18]

Scenarios Favoring Neither (Reassess the Entire Regimen)

A patient with T1D who has been misclassified as T2D should not receive empagliflozin at all outside clinical trials. A patient with active DKA, severe renal impairment (eGFR <30 mL/min/1.73 m²), or high surgical risk may need temporary insulin monotherapy until the clinical situation stabilizes.

Monitoring Plan for Patients on Both Drugs

Clinicians managing patients on the empagliflozin plus glargine combination should follow a structured monitoring schedule.

At initiation: fasting glucose daily (patient self-monitoring), HbA1c at 3 months, basic metabolic panel (creatinine, potassium, bicarbonate) within 4 weeks, blood pressure at every visit.

At 3 months: HbA1c, assess for genital symptoms, confirm adequate glucose tablet availability, review hypoglycemia log, reassess glargine dose against fasting glucose average.

Ongoing (every 6 months): HbA1c, eGFR, urine albumin-to-creatinine ratio, lipid panel, foot exam, ophthalmology referral per ADA schedule. [13]

Bicarbonate level deserves special mention. A bicarbonate below 18 mEq/L in a patient on an SGLT2 inhibitor should trigger measurement of serum ketones and urine ketones to rule out euglycemic DKA, even if glucose is normal. [15]

Cost, Access, and Formulary Considerations

Empagliflozin (Jardiance) carries a list price of approximately $600, $650 per month without insurance, though manufacturer co-pay programs and pharmacy discount cards (GoodRx) frequently reduce out-of-pocket costs to $10, $50 per month for commercially insured patients. Generic empagliflozin received FDA approval in 2024, with market entry expected to lower costs substantially within 12 to 24 months. [19]

Insulin glargine U-100 (Lantus) remains available at a list price of approximately $280, $300 per vial, though biosimilar alternatives (Basaglar, Semglee, Rezvoglar) are priced 15 to 20% lower. [20] The $35/month insulin cost cap enacted under the Inflation Reduction Act of 2022 applies to Medicare Part D beneficiaries for any covered insulin product, including glargine biosimilars.

Formulary status varies widely by payer. Prior authorization requirements for SGLT2 inhibitors are common among commercial plans, and denial rates run as high as 20 to 30% on first submission without documented ASCVD, HF, or CKD indications.